Live Breaking News & Updates on Adventhealth Medical Group Radiation Oncology

Stay updated with breaking news from Adventhealth medical group radiation oncology. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

FDA Approval Insights: Toripalimab in Recurrent/Metastatic Nasopharyngeal Carcinoma

Drs Hanna and Kandula discuss the significance of the FDA approval of toripalimab in nasopharyngeal carcinoma; pivotal data from the JUPITER-02 and POLARIS-02 trials; and how this regulatory decision increases the importance of multidisciplinary collaboration. ....

Dana Farber Cancer Institute , United States , Shravan Kandula , Ashling Wahner , Glennj Hanna , Harvard Medical School , Cancer Therapeutic Innovation Early Drug Development Program , Live On Air , Cancer Therapeutic Innovation , Early Drug Development Program , Rare Head , Neck Cancers , Adventhealth Medical Group Radiation Oncology , Central Florida , Drs Hanna , Onclive On Air , Apple Podcasts , Google Podcasts , Amazon Music , Fda Approval Of Toripalimab In Nasopharyngeal Carcinoma , Jupiter 02 Trial , Polaris 02 Trial ,

Toripalimab Approval Pioneers Immunotherapy Use in Nasopharyngeal Cancer

Nabil F. Saba, MD, FACP, and Shravan Kandula, MD, highlight the significance of the approval of toripalimab for nasopharyngeal carcinoma; key data from JUPITER-02 and POLARIS-02 trials; and how the addition of this agent to the treatment armamentarium heightens the importance of multidisciplinary collaboration. ....

Emory University , United States , Nabilf Saba , Junshi Biosciences , Coherus Biosciences , Howard Halpern , Shravan Kandula , Neck Cancer Multidisciplinary Program , Department Of Hematology , Neck Cancer Research , Medical Oncology , Emory University School , Howard Halpern Chair , Winship Cancer Institute , Adventhealth Medical Group Radiation Oncology , Central Florida , Shanghai Junshi , Chenq Y , Chend P , Pd 1 Inhibitor , Nasopharyngeal Carcinoma , Phase 3 Jupiter 02 Trial Nct03581786 , Phase 2 Polaris 02 Trial Nct02915432 ,